ESLA Estrella Immunopharma, Inc. - Common Stock
$1.11
Price · May 20, 2026
Fundamentals as of May 18, 2026
52W Range
$1–$3
14% of range
Analyst Rating
BUY
7 analysts
Price Target
$12
+981% upside
P/E (TTM)
-4.5
ROE
—
Net Profit Margin
—
ESLA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.11
Market Cap
—
P/E (TTM)
-4.5
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$1 – $3
ESLA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ESLA
Peer Median
P/E (TTM)
-4.5
0.9
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ESLA
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ESLA
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ESLA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ESLA
Peer Median
ESLA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
1 analysts · 2026-05-19
Low
$12.00
High
$12.00
Median target
$12.00
+981.1%
Mean target
$12.00
+981.1%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.05%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| Dec. 31, 2025 | $-0.35 | $-0.18 | -0.17% |
| Sept. 30, 2025 | $-0.13 | $-0.19 | 0.06% |
| June 30, 2025 | $-0.35 | $-0.18 | -0.17% |
| March 31, 2025 | $-0.06 | $-0.11 | 0.05% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ESLA | — | -4.5 | — | — | — | — |
| KALA | $15M | -0.2 | — | — | -1423.8% | — |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | — |
| MGX | $61M | -0.7 | -51.8% | -348.5% | -49.6% | — |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | — |
| GRML | — | — | — | — | -104.9% | — |
| PSTV | $71M | -1.8 | -10.5% | -429.4% | -636.9% | — |
| TVGN | — | — | — | — | — | — |
| ATOS | $5M | -0.1 | — | — | -71.7% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 11
| Metric | Trend | 2025 |
|---|---|---|
| Prepaid Expense | $292.7K | |
| Current Assets | $2M | |
| Total Assets | $3M | |
| Current Liabilities | $14M | |
| Total Liabilities | $14M | |
| Common Stock | $3.8K | |
| Paid-in Capital | $27M | |
| Retained Earnings | $-37M | |
| Treasury Stock | $598.4K | |
| Stockholders' Equity | $-10M | |
| Liabilities + Equity | $3M |
Valuation (TTM) 3
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $-13M | |
| P/E | -4.5 | |
| Earnings Yield | -22.4% |
Income Statement 11
| Metric | Trend | Q1 2026 |
|---|---|---|
| R&D Expense | $1M | |
| SG&A Expense | $891.8K | |
| Operating Expenses | $2M | |
| Operating Income | $-2M | |
| Pretax Income | $-2M | |
| Net Income | $-2M | |
| EPS (Basic) | $-0.05 | |
| EPS (Diluted) | $-0.05 | |
| Shares (Basic) | 42,121,075 | |
| Shares (Diluted) | 42,121,075 | |
| EBITDA | $-2M |
Balance Sheet 11
| Metric | Trend | Q1 2026 |
|---|---|---|
| Prepaid Expense | $229.8K | |
| Current Assets | $2M | |
| Total Assets | $4M | |
| Current Liabilities | $9M | |
| Total Liabilities | $9M | |
| Common Stock | $4.3K | |
| Paid-in Capital | $35M | |
| Retained Earnings | $-39M | |
| Treasury Stock | $598.4K | |
| Stockholders' Equity | $-5M | |
| Liabilities + Equity | $4M |
Cash Flow 5
| Metric | Trend | Q1 2026 |
|---|---|---|
| Stock-based Comp | $146.7K | |
| Operating Cash Flow | $-7M | |
| Stock Issued | $8M | |
| Net Stock Activity | $8M | |
| Financing Cash Flow | $7M |
Profitability 2
| Metric | Trend | Q1 2026 |
|---|---|---|
| ROA | -75.1% | |
| ROE | 64.5% |
Liquidity & Solvency 1
| Metric | Trend | Q1 2026 |
|---|---|---|
| Current Ratio | 0.2 |
Valuation (TTM) 3
| Metric | Trend | Q1 2026 |
|---|---|---|
| Net Income TTM | $-15M | |
| P/E | -2.7 | |
| Earnings Yield | -36.8% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.